Results 151 to 160 of about 12,091 (231)

Comprehensive High-Sensitivity Mutation Profiling in MPNs: Diagnostic and Prognostic Implications. [PDF]

Cancers (Basel)
Kim N, Kang Y, Kook HW, Chung H, Jang JE, Lee ST, Song J, Kim JS, Choi JR, Cheong JW, Shin S.   +10 more
europepmc   +1 more source

Platelet Proteome Links Metabolism to Reactivity in Essential Thrombocythemia. [PDF]

Mol Cell Proteomics
Guerrero-Carreño X, Smits S, Esteban Lasso A, Samiotaki M, Calabuig-Navarro V, Iborra FJ, Rantanen F, Álvarez-Larrán A, Angona Figueras A, Bellosillo B, Sáez Marín AJ, García-Gutiérrez V, Dekkers DHW, Demmers JAA, Ferrer-Marín F, Hernández-Boluda JC, Matsakas A, Benavente Cuesta C, Vandenberghe P, Papadopoulos P.   +19 more
europepmc   +1 more source

CALR NM_004343.3:c.1092_1143del52 [PDF]

, 2020
openaire   +1 more source

The Roles of Genetic and Epigenetic Abnormalities in Essential Thrombocythemia. [PDF]

Genes (Basel)
Strzała D, Homenda W, Połom A, Kellas A, Bilska S, Paszek S, Potocka-Wojtowicz N, Zawlik I.   +7 more
europepmc   +1 more source

Inhibitory HLA-C/KIR2DL2 Interactions and KIR Allelic Polymorphisms Are Associated With Susceptibility to Philadelphia Chromosome-Negative Myeloproliferative Neoplasms. [PDF]

EJHaem
Shivarov V, Tsvetkova G, Hadjiev E, Ivanova M.   +3 more
europepmc   +1 more source

Resolving diagnostic uncertainty in rare MPL and CALR variants: A practical framework for the haematology clinic. [PDF]

Br J Haematol
Singh S, Dhillon BK, Pandita RM, Jain K, Singh J.   +4 more
europepmc   +1 more source

Frequency of Non-Type I/II <i>CALR</i> Mutations in Patients Undergoing Molecular Diagnostics for Myeloproliferative Neoplasms. [PDF]

Diseases
Makarik T, Nikulina E, Treglasova S, Stepanova E, Chernova N, Biderman B, Kokhno A, Sudarikov A.   +7 more
europepmc   +1 more source

Artificial Intelligence Based High Resolution Melting Analysis for Comprehensive Calreticulin Mutation Screening and Novel Variant Detection in Myeloproliferative Neoplasms. [PDF]

Int J Lab Hematol
Zhang Q, Ma X, Wu Q, Duan Y, Yang C, Tang X, Xu C, Guan M, Wu Z.   +8 more
europepmc   +1 more source

CALR NM_004343.3:c.1154_1155insTTGTC [PDF]

, 2020
openaire   +1 more source

Emerging agents and regimens for myeloproliferative neoplasms: updates from ASH 2025 Annual Meeting. [PDF]

Exp Hematol Oncol
Zhang T, Jiang H, Liu D.
europepmc   +1 more source